Azithromycin microspheres 2.0 single dose
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Community-Acquired Pneumonia
Conditions
Community-Acquired Pneumonia
Trial Timeline
Sep 1, 2005 → Jun 1, 2006
NCT ID
NCT00140023About Azithromycin microspheres 2.0 single dose
Azithromycin microspheres 2.0 single dose is a phase 3 stage product being developed by Pfizer for Community-Acquired Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT00140023. Target conditions include Community-Acquired Pneumonia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00140023 | Phase 3 | Completed |
Competing Products
9 competing products in Community-Acquired Pneumonia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ONO-5046Na + ONO-5046Na | Ono Pharmaceutical | Phase 2 | 52 |
| Ceftaroline + Ceftriaxone | Pfizer | Phase 3 | 76 |
| IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacin | Pfizer | Approved | 84 |
| Azithromycin SR | Pfizer | Phase 3 | 76 |
| Azithromycin SR + Amoxiclav | Pfizer | Pre-clinical | 22 |
| tigecycline | Pfizer | Phase 3 | 76 |
| Tigecycline + Levofloxacin | Pfizer | Phase 3 | 76 |
| Omadacycline + Moxifloxacin | Zai Lab | Phase 3 | 72 |
| ceftobiprole medocaril + IV standard-of-care cephalosporin | Basilea Pharmaceutica | Phase 3 | 72 |